Analysis of the PetMeds Board
PetMed's board seems to have been assembled with shareholder value, strategic capabilities, and operational expertise in mind.
"There Are No Bad Assets, Just Bad Prices."
Analysis of the PetMeds Board
PetMed's board seems to have been assembled with shareholder value, strategic capabilities, and operational expertise in mind.
PetMed Express (PETS) is a declining pet pharmacy and pet healthcare company. The current market valuation fails to account for several factors. Such as cash, real estate, prior acquisition interest, and signs of turnaround efforts. Two prior acquisition bids were $4-4.25 per share. Yes, revenue and margins were declining. And the share price has fallen. Further, concerns have increased due to competition. The current valuation suggests investors are forecasting a significant deterioration in the franchise. Execution risk is substantial. Although the existing assets provide material downside support. Continued operating losses will quickly reduce the margin of safety.
PETS lacks a permanent CEO. Or an interim CEO with experience in the pet pharmacy industry. Leadership stability is critical to turnarounds. An interim CEO makes for additional activist or new acquisition talks. Interim leadership might emphasize immediate value realization over long-term transformation.
Risks:
According to the latest 10Q, revenue fell 22.7%, and reorder sales declined 22.6%. Operating cash flow was –$23.7M. The $26.7M in goodwill was fully impaired due to lower forecasts and a declining market value. The $2.1M inventory write-down indicates operational errors. With interim leadership, it's hard to turn a company around.
PETS is a high-risk turnaround. The business is shrinking. Although the balance sheet provides time. The stock trades at around $2.20, with a market cap of $46M and an enterprise value of $19.22M. Latest data show cash fell from the prior-year balance of $ 54.72M to $26.9M due to negative operating cash flow.
Additional risks include permanent customer losses to competitors such as Chewy and Amazon. And failure to successfully integrate PetCareRx, continued cash burn, lack of permanent leadership, margin pressure from pricing competition and discounting, and possible further impairment of brand value
PETS is mostly an asset backed special situation.
Management initiatives include cost reductions, PetCareRx integration, autoship expansion, digital improvements, and veterinary offerings.
The market price ignores the values of owned assets. PETS has $26.9M in cash, $12.2M in inventory, $1.6M in accounts receivable, $27.6M in property and equipment, and $32.8M in shareholder equity. Liabilities consist of normal operating costs rather than debt obligations. Investors are overlooking asset values that exceed GAAP.
The company owns its 14.60-acre Delray Beach, Florida headquarters and distribution facility, along with 2 acres of excess land. Based on comparable South Florida industrial and commercial property values. The Delray property may be worth approximately $35M. Although the exact market value is uncertain. This creates potential upside with a sale-leaseback or renewed outside interest.
For the nine months ended December 31, 2025, PETS generated $136.2 million in sales. Reorder sales were $112.7 million, representing approximately 83% of total sales. New order sales were $18.6 million, while membership fees contributed $4.9 million. The revenue continues to come from existing and repeat customers.
Additional assets include the PetMeds brand and PetCareRx trade name. And internet domains, toll-free customer assets, and a $5.3M investment in Vetster. Additionally, management reduced costs and inventory by integrating PetCareRx. Digital operations are improving, and Telehealth is expanding. Inventory dropped from $16.2M to $12.2M. When an asset-heavy company trades below its estimated private value. Strategic outcomes, such as the sale of the company, increase.
SilverCape announced in December 2025 that it would take PETS private for $4.00 a share. And changed its 13G status to 13D, making it the largest outside investor. They increased their ownership stake to 12.20% (2,579,696 shares). Management stepped up and used a poison pill to prevent SilverCape from acquiring more than 13% of the outstanding shares. Soon after, Cardone Ventures submitted a cash offer of 4.25. Cardone mentioned the value of the PETS brand. Including its customer relationships, pharmacy platform, and operating infrastructure. Other major value investors have also acquired positions. Nina Capital owns about 8.8% and has added to its position through open-market purchases. Pinnacle Value Fund acquired a position in 2025 at an average price of $2.84 per share. As of February 2026, Diveroli Investment Group owned 391,757 shares, equal to roughly 1.83% of PETS.
There is also reason to believe that acquisition discussion may still be possible. SilverCape's proposal said it would "engage constructively" with the Board and management. Furthermore, neither management nor SilverCape publicly stated that negotiations or discussions had ended. Because SilverCape still owns over 12% of the company, strategic discussions cannot be ruled out. Although there is no public evidence that negotiations continue. We shouldn't discount the possibility of PETS going private.
Sum of the parts valuation
Valuation Ratios
With any hint of turnaround success, the valuation will increase substantially.
Additional reasons for a higher valuation:
Reorder sales are 83% of total sales. PETS still owns customer relationships and brands. There is no debt burden, although its operating liabilities are large. And the Delray property may be worth over 40M.
The margin of safety is supported by cash, real estate, customer assets, and a minority investment in Vetster. Significant upside still may depend on management stabilizing operations and converting repeat customers into sustainable profits.
Precision Optics is transforming from a niche engineering supplier to a large manufacturer. If management executes effectively. This transition could drive outsized earnings growth and a higher stock price.
The recent $10M public stock offer at $3.60 was oversubscribed. Investors included existing shareholders and new value institutional investors. Further, the CEO, CFO, COO, and directors bought shares in the recent offering at the same terms as outside investors.
Now the question for investors. Can POCI transform from a thinly traded microcap into a small med tech growth company?
The transformation is becoming more visible when looking at the prior 3 quarters. Q1 2026 revenue was 6.70M, Q2 2026 was 7.4 M, and the most recent reported Q3 2026 was 8.70M. Gross margins also had a major recovery, from 14.40% in Q1, 2.80% in Q2, and 24% in the most recent Q3 2026. Adjusted EBITDA went from negative to positive in Q3 2026.
Risks:
Execution remains the largest risk and is discussed during conference calls. Management highlighted low yields, scrap costs, labor inefficiencies, and training challenges. Gross margins fell to 2.8% in Q2, and EBITDA guidance shifted from a projected profit to a meaningful loss. This suggests management underestimated the difficulty of scaling.
Customer concentration remains significant. A large portion of revenue depends on a small number of customers. During Q3, an aerospace customer requested a temporary production slowdown. This shows how results can change if a key customer delays or reduces orders. While recent financing has improved liquidity, dilution risk has not disappeared. And capital may be needed if profitability takes longer than expected. POCI is a small manufacturer. It is struggling to prove it can convert revenue growth into sustainable earnings
Opportunities:
Precision Optics is transitioning from a small engineering company to a production manufacturer. Potentially creating attractive operating leverage.
Management stated that we are operating at a record level on the latest Q3 2026 conference call. This was evident as revenue increased from $6.7 million in Q1, $7.4 million in Q2, and to a record $8.7 million in Q3 2026.
POCI's aerospace business may be a valuable hidden asset. Its satellite-related programs generate roughly $3.6 million in quarterly revenue. And production yields are improving to 97%. This implies an annual revenue run rate of $14-15 million for a single customer. In addition to aerospace, the company supports attractive medical markets. Such as cystoscopes, ophthalmic devices, arthroscopy, urology, and otoscopy. Management says these segments are growing at mid to high-teen annual rates. Furthermore, medical products create sticky customer relationships. Because of their long product life cycles and regulatory barriers. Also, the recent $10 million financing reduces near term financial risk.
Valuation Metrics:
Comparison to Peers
POCI = 52 Week price change = 6.43%,current ratio = 2.10, book value 2.10, revenue per share = 3.10,quarterly revenue growth (yoy) = 108.00%
Management's technical background and shareholder alignment provide a foundation as the company moves from a niche engineering business into a larger manufacturing operation. From 2006 to 2011, the CEO was the company's Executive Vice President and Chief Scientific Officer. He earned a PhD in Applied Physics from Princeton University, and he holds an MA in Mechanical/Aerospace Engineering. He's an optical and imaging guy, so his background makes sense.
I started with a long position in POCI. POCI is a high risk idea. But I would recommend POCI as a speculative investment.
Innovative Food Holdings (IVFH) is a nanocap specialty food distributor undergoing a more focused asset-light model. Shares trade at $0.82 with 54.8 million shares outstanding and a market value of $44.9 million. Public float is 28.7 million shares or 23.5 million.
By selling their Pennsylvania warehouse and closing the unprofitable cheese business in 2025, management proved they can make difficult pro-shareholder decisions. Eliminating the Pennsylvania warehouse will yield quarterly savings of approximately $200,000 in interest, while closing the unprofitable cheese business will enhance gross margins.Further, management is growing the Digital Channels business, which adds more products and vendors without inventory. Their use of AI helps accelerates onboarding,jumping from 13 items historically to 400 items added in just four weeks. Meanwhile, the airline catering segment grew 26% year-on-year.
A debt-free balance sheet, margin recovery, a scalable platform, and multiple expansions create a higher stock price.
Business Overview:
Innovative Food Holdings (IVFH) distributes specialty foods through an asset-light digital network (Sysco, US Foods, Amazon) and a fast-growing airline catering arm (+26% YoY, Q2 2025). Recent acquisitions (Golden Organics, LoCo) have expanded regional capacity and fed into its digital catalog. Meanwhile, the airline business is consolidated in Chicago for efficiency.
Recent Developments (Q2 2025)
IVFH posted $21.1M revenue (+27% YoY) with airline catering up 26% and Amazon triple-digit growth; the remaining improved sequentially. Reported gross margin was 21% but ex-cheese margin expanded by 66 bps. OCF turned positive (+$575K vs. -$977K in Q1), net income swung to $59K, and the cheese exit plus the pending PA warehouse sale (Sept. 2025) set up lean, higher-margin operations.
Catalyst:
The following two quarters, ~$9M of debt is retired by Q4 2025, reducing ~$200K/quarter in interest expense and leaving IVFH nearly debt-free. The exit from the unprofitable cheese business removes a structural drag, while the Chicago consolidation unlocks SG&A leverage and pushes margins toward the mid-20s. At the same time, AI-driven catalog expansion accelerates growth, with onboarding speed cut by ~80% and thousands of high-margin SKUs ready to launch. Airline catering continues to compound (+26% YoY) with embedded recurring revenue and ongoing customer wins adding upside. With valuation at just 0.66× EV/Sales-well below peers at 1-2×-and normalized EBITDA power set to re-rate sharply, the timing offers investors a rare window before cleaner results and balance sheet optics force the market to close the gap.
Ownership
Activist shareholders with skin in the game on the board is a game changer.Innovative Food Holdings has unusually aligned ownership for a turnaround.
Pappas owns 18% of the company's shares and has been on the board since 2020. His background in restaurants and distribution makes IVFH an easy fit for his playbook. He's a proponent of "growth activism" - fixing capital structures, installing operators, and aligning governance with customers.
Bandera Partners holds ~12% and Denver Johnson Smith ~9%. Inlight Wealth (~5%) and Intelligent Fanatics (~5.5%) add to the institutional sponsorship. Collectively, these funds control >45% of equity. Insider alignment is meaningful: CEO Bill Bennett owns ~4.5%, COO Brady Smallwood holds option grants based on performance, and director Hank Cohn retains ~5%. The result is a concentrated, shareholder-friendly register where activists and management align economically. Active ownership is critical. The company misallocated and devalued assets for years. It anchors capital discipline, enforces board refreshment, and supports operating playbooks built for growth. Large value-oriented shareholders directly impact strategy and capital allocation. Value-based activist ownership will guide improved capital allocations, forcing a clear path to create long-term value.
Valuation:
At just 0.66× EV/Sales, IVFH trades at a steep discount to distribution peers Sysco (1.0×), US Foods (0.9×), and Performance Food Group (0.8×). A re-rating to 1.0× implies ~50% upside. At $0.82/share, IVFH offers material upside with multiple opportunities to accelerate growth and margin expansion.
Risks:
Margin and growth risks include accelerated catalog growth and recent acquisition integrations. Customer concentration remains a factor, with U.S. Foods still representing a large distribution channel and subject to competitive pressure. As a thinly traded small-cap, IVFH shares carry liquidity, risk and volatility. Finally, the expected synergies from the Denver acquisition have not yet been proven, leaving room for integration challenges if management falls short.
Conclusion:
IVFH is an overlooked micro-cap entering a turnaround phase. Multiple catalysts, including debt elimination, AI-driven catalog expansion, airline catering growth, and margin recovery, are set to re-rate the valuation. At just 0.66× EV/Sales, the stock trades well below its peers despite intrinsic value estimates pointing to 2-3× upside. A small, ignored company undergoing a balance sheet and operating reset, where execution through Q4 2025 and after creates potential for asymmetric returns.
Long:IVFH
Today's post updates the risks and opportunities associated with the recent real estate sale and also contains a message for the Chairman of the board.
Business Summary:
Tandy Leather announced on Dec 6th that its corporate
headquarters was sold for $26.5 million before taxes/expenses. The expected
closing date is sometime in January 2025. As part of its transition to new
facilities in Fort Worth, Texas, Tandy will lease back the facilities until
September 2025.
The announcement had a minimal impact on TLF's stock price.
Before the announcement, the stock traded at approximately $4.20 per share over
the trailing three months. Following the sale announcement, the price rose
modestly to $4.75 per share. Given the stock’s limited trading volume, even
this increase lacked significant momentum.
This muted market reaction is surprising, especially
considering that the company’s liquidation value, by my conservative estimate,
increased by 42%. This estimate assumes $15 million in additional net cash
proceeds from the sale, based on a pre-announcement value of $35 million. My
calculation factors in estimated real estate taxes and expenses of $11.5
million, leaving $15 million in net cash proceeds.
Dear Mr. Chairman,
I have been a dedicated shareholder of Tandy for many years,
but I am increasingly concerned about the board’s operational oversight and
strategic decision-making. My concerns stem from significant missteps,
including the mishandling of inventory errors and the substantial expenditure
on consultants, which squandered shareholder value.
The current CEO is 63 years old, and two CFOs have been
hired and departed within two years. This instability raises serious questions
about the board’s ability to identify and retain competent leadership for key
positions. Why should shareholders trust the board to effectively replace a
future CEO or CFO? Furthermore, how does the board intend to responsibly
allocate proceeds from the headquarters sale, valued at $26.5 million?
Accountability for Inventory Errors
I believe the removal of former CFO Ms. Castillo following the discovery of
inventory errors in Q4 2019 was a mistake. Despite this, the board has not
taken accountability for the multi-year inventory errors or the lack of
compliant systems that led to them. As a fiduciary body, the board is
responsible for overseeing inventory management, ensuring system compliance,
and approving budgets for improvements. Yet, the company relied on outdated,
non-integrated systems—some stores even maintained paper records. These
shortcomings culminated in regulatory penalties and significant value
destruction, further eroding shareholder trust.
Financial Oversight Gaps
Since 2020, Tandy has recruited and lost two CFOs. These hires were
ill-suited for the role, as evidenced by their short tenures. This reflects a
glaring gap on the board—a lack of members with real-world corporate finance
and operational experience. This deficiency has directly contributed to ongoing
accounting irregularities. Why was Ms. Castillo removed in the first place, and
how can shareholders trust the board to effectively select a new CFO given its
track record?
Compensation Discrepancies and Shareholder Concerns
In FY 2023, Tandy, a $35 million nano-cap company, paid its CEO and a board
member $1,181,280 in total compensation. The CEO now holds 439,285 shares, or
5.22% of shares outstanding, alongside generous annual stock options—such as
92,000 shares in 2022 with an exercise price of $3.52. These figures appear
disproportionate to Tandy’s size and performance, particularly in light of the
challenges faced since the discovery of inventory errors.
Cash Balance Decline and Cost Mismanagement
When inventory errors were identified in Q4 2019, Tandy’s audited cash
balance stood at $25 million. By September 2022, when Tandy was relisted on
NASDAQ, this had plummeted to $3 million. While inventory valuation issues did
not impact cash directly, the precipitous decline reflects significant
mismanagement. Currently, the cash balance sits at $10 million. What specific
actions contributed to this erosion of cash reserves?
From 2019 to 2020, the company spent $5.5 million on
restatement efforts and CFO transitions. Over two years, an additional $4.9
million was allocated to restatements, with $594,000 earmarked for CFO-related
expenses, as disclosed in the 10-K. Despite these investments, the board failed
to ensure the implementation of effective ERP and accounting systems, leading
to ongoing inefficiencies and delays.
Relisting and Additional Costs
Tandy was delisted from NASDAQ in August 2020 after the board failed to
prepare timely financial statements. It took nearly two years—and significant
costs for financial consultants, ERP system advisors, and CFO transitions—for
the company to regain its listing in July 2022. Between 2019 and 2022, millions
of dollars were spent without clear disclosure of consultant costs, further
frustrating shareholders.
The board must address these systemic failures and
communicate a transparent plan for the future. As a shareholder, I urge you to
take immediate action to restore confidence by improving oversight, ensuring
accountability, and demonstrating a commitment to responsible financial
stewardship.
Shareholders are not unreasonable in believing the upcoming
cash infusion will evaporate. Furthermore, the proposed small dividend would do
little to offer meaningful liquidity to long-term shareholders who have
patiently supported the company for years.
Opportunities
The board must recognize that Tandy Leather Factory (TLF) is
not suited to remain a publicly listed company. However, due to inertia, the
company continues to bear unnecessary administrative and operational expenses,
which serve no real benefit to shareholders or employees. A strategic sale of
Tandy would unlock significant value and position the company for long-term
health and growth under more suitable ownership.
Tandy's future lies with an entity capable of nurturing its
potential for the benefit of all stakeholders. Based on NAV or EBITDA multiple
valuations, Tandy could command a premium of over 65% above its current market
value.
A new owner could realize over $1 million in annual savings
by eliminating public company costs, including listing fees, audits, and legal
expenses. These savings alone would contribute to immediate profitability
improvements.
Since 2018, Tandy's EBITDA margins have averaged
approximately 6.75%, generating an annual EBITDA of $5.4 million. However, for
the 17 years prior, EBITDA margins averaged a much stronger 12.6%. If a new
owner can drive modest revenue growth—boosting the current $76 million average
revenue to $80 million—and restore historical EBITDA margins to 12%, Tandy’s
annual EBITDA could reach $10 million.
This approach not only enhances operational efficiency but
also provides a sustainable foundation for growth, benefiting employees,
customers, and investors alike. The path forward is clear: a strategic sale
would unlock Tandy's true value and secure its future.
Valuation using the Balance Sheet
These metrics all point to a much higher valuation over the current 38M.
Conclusion: NOW is the time to explore strategic alternatives.
I respectfully urge the Board of Directors to engage in a
thorough review of strategic alternatives, including the potential sale of the
company, to maximize shareholder value and ensure the long-term interests of
all stakeholders are prioritized
The board must urgently develop and present a transparent
plan to ensure shareholders have the opportunity to exit at a fair and
reasonable price – no less than $7 per share. If the board cannot
achieve this without pursuing a sale of the company, then it is imperative they
explore and initiate a formal sale process without delay.
As Benjamin Graham wisely noted in Security Analysis:
"It is not the function of the corporation to make the market for its
shares, but it should provide a fair and reasonable opportunity for
stockholders who desire to dispose of their holdings to obtain an adequate
price for them."
Currently, minority shareholders are being neglected and
undervalued by Tandy’s board. This has persisted for far too long. Mr.
Chairman, it is time to demonstrate goodwill and take meaningful action to
address shareholder concerns.
Long TLF
HireQuest (HQI)
Price = $14.48: Market Cap = 200.16M : Enterprise Value = 215.19M
HireQuest (HQI) is a fast-growing national staffing franchisor with a proven, profitable asset-light model. It has impressive historical operating margins and strong free cash flow. The CEO’s net worth is invested in +22% of HQI’s outstanding shares. His total HQI investment is 44 million, and he often makes open market purchases.
The staffing industry is highly fragmented. And HQI has aggressively made strategic acquisitions, buying smaller competitors and integrating them into its franchise model. Refranchising acquired companies boosts profits by lowering the capital requirements, costs, and operating risk.
Top-line growth is evident. Revenue per share increased by 126.22% from the 2021 balance of 1.15 to the trailing twelve-month balance of 2.61. Profitability has materially grown. Per share, retained earnings, and book value grew by 283.09% and 87.54%, respectively, from 2021 to the current trailing 12 months. These value-increasing attributes have significantly outperformed its stock price performance, offering a mean reversion opportunity in addition to expanding multiples and value from additional growth. HQI’s price per share declined -23.01 % from the year ending 2021 to the current price of $14.25, contrasted to the material per share value improvement in retained earnings, book value, revenues, and a forward dividend yield of 1.68%. HQI declared a .06 dividend for shareholders of record 12/2/24.
Relative valuation using the NAISC code 561311 (employment placement agencies) for 14 companies.
Economic downturns can reduce staffing demand.
Opportunities:
Through franchising, HQI can enter diversified staffing verticals and grow.
They can boost margins by buying and converting to their proven asset-light business model.
The expanded national network enhances HQI’s ability to secure large contracts.
Franchises make HQI resilient to economic downturns. Companies may prefer temporary staffing solutions to full-time hires.
S&W Seed (SANW) is a global agricultural business focusing on alfalfa, sorghum, pasture, and sunflower seeds. It develops proprietary products using plant breeding and molecular techniques and sells over 600 seed products. Cleaning and processing facilities are located in Texas, New South Wales, and South Australia. S&W seed products are sold in over 40 countries, and management expects to introduce 20 new products during 2024.
In June 2023, SANW hired Mark Herrmann as their CEO. With a remarkable 35 years of experience in the seed industry, including a significant tenure at Monsanto, Mark brings a wealth of knowledge and a fresh perspective to our team. His recent role as the CEO/Founder of ACUMEN and AgReliant Genetics further underscores his leadership capabilities and his potential to steer S&W Seed toward greater success.
The Double Team technology platform by S&W Seed (SANW) improves profitability and productivity
for sorghum grain farmers. Sorghum requires
less water and energy than other crops like corn. The technology also helps
farmers optimize their use of resources, leading to better profitability.
The table below provides additional quantitative value analysis.
Properties owned: Warehouse ( Moore County, Texas); Processing facility/Warehouse (Lubbock County, Texas); Research farm (Keith, South Australia)
S&W Seed has demonstrated impressive growth with Double Team and its future product pipeline. Strategic partnerships and focusing on high-margin products with low-cost partnerships and associated royalties offer value for investors willing to take on the risk.
Despite this, we cannot predict droughts, floods, geopolitical issues, or market acceptance of their current or future products. This, coupled with current debt, makes SANW a HIGH RISK investment.
However, given the current valuation and current and potential value of existing seed technology, I consider SANW a POSITIVE EXPECTED VALUE INVESTMENT. So, I'm buying SANW.
Long SANW (S&W Seed Company)
Kambi provides sports betting technology worldwide. Over 40 operators on six continents are part of their partnership. From compliance to odds-compiling, Kambi offers a wide range of services through its in-house software platform. Over 1,000 employees work at eight global locations: Malta (headquarters), Australia, Copenhagen, the Philippines, Romania, Sweden, the UK, and the US.
My analysis is only quantitative and needs more work. I'm not making a recommendation but instead for additional research if interested.
Over the past few years, Kambi has lost its three largest customers. Kindred, Penn Entertainment, and DraftKings have purchased or developed internal solutions. However, the current price may offer an opportunity. The market may have overestimated the risk of Kambi's customers sourcing their sportsbook technology.
.
Enterprise value per share is 8.89. That's a decline of 71.12% from 30.77 at the end of 2020. Retained earnings per share rose 200.20% over the same period, from the MRQ balance of 4.66 versus the 2020 balance of 1.46. Ratios also improved, EV/Rev = 1.40 (85.46% improvement from 2020), EV/GP = 1.42 (66.60% improvement from 2020), and EV/Retained earnings = 1.91 (76.51% improvement from the 2020 balance of 21.11).
Kambi offers barriers to entry and switching costs. With its current low valuations, it could be an acquisition candidate.
JACK: Jack In The Box
Jack in the Box was founded in 1951 and operates and franchises fast food restaurants, Jack in the Box and Del Taco, throughout the U.S. The company is based in San Diego, California.
Jack in the Box is transforming from an asset-heavy and barely growing to a faster-growing, asset-light franchisor that is shareholder-friendly by monetizing real estate assets, dividends and improving its capital structure with share repurchases.
In addition to 189 restaurant-owned land locations, JACK owns its corporate headquarters in San Diego, California. The headquarters is 70,000 square feet and contains approximately four acres of undeveloped land. Its fair market value is around 40 million. Rent is earned at the land locations owned by JACK and used by the franchisee.
IMO, at these prices, Jack in the Box stock is a weak intermediate-term buy and a stronger long-term buy. There's a high debt load, no obvious valuation discount to peers, and rising inflation for food and labor. Demand for fast food is weak, and the market is highly competitive.
Expensify (EXFY) develops and sells Software-as-a-Service (SaaS) solutions designed to simplify expense reporting, receipt tracking, global payments, and company card reconciliation. The platform streamlines the financial expense management workflows. Expensify's features include payment processing, invoicing, chat, document management, global reimbursements, budgeting, and email notifications. Employees can easily report payments and receipts, allowing finance departments to track, analyze, and manage budgets more effectively.
Why Expensify (EXFY)? Expensify is a broken October 2021 IPO. Financially strong and valued at 125M as a Software-as-a-Service (SaaS). It's down 96% from its first week high as an IPO. However, EXFY trades at an EV/Rev of .83 with an average of 719,000 2023 paid members and $1,116,296 revenue per employee. FCF is projected to be between 10 and 12 million in 2024. Further, a clear road map and focus on dominating the untapped, underserved VSB (very small business) market that uses email and Excel to manage expenses and documents. New Expensify created a moat around payments and documents with real-time chat in 2024. In 2023 and 2024, Steven Mclaughlin (Founder / CEO / Financial Technology Partners) purchased 11,341,889 shares above the current market price.
The full-year 2023 financial results were reported on 02/2024. Revenue was 150.70 million, operating cash flow was 1.60 million, and FCF was 600,000. GAAP net loss was $41.7 million, non-GAAP net loss was $500,000, and adjusted EBITDA was 13.20 million. Adjusted EBITDA excludes stock compensation, depreciation/amortization, interest expense, and taxes.
Quarter 4 revenue was 32.2 million, average paid members was 719,000, net loss was 7.50 million, and adjusted EBITDA was 5.90 million. The fourth quarter demonstrated material improvement over Q3, driven by expense reductions. Cash used in operations was $500,000. Free cash flow was negative at $3.6 million, and net loss was $7.5 million. Non-GAAP net income was $3.1 million, and adjusted EBITDA was $5.9 million.
Adds, Churn, Expansion (FY 2022 and 2023)
The slide above was taken from Q4 2023 earnings call
Key metrics, like churn and new acquisitions, averaged the same over the prior two years. However, customer growth fluctuated materially, with a decline in paid seats compared to the previous year. The contraction of paid seats among existing customers resulted from challenging economic conditions reported by management. Despite economic conditions, customers stayed; instead, they made fewer and smaller transactions.
Tandy Leather, symbol TLF, founded in 1919, is a consistently profitable leather crafting retail leader. Tandy sells leather and leather craft-related items primarily through retail stores, websites, or direct account representatives. Tandy has 101 stores in 40 states, six provinces in Canada, and one store in Spain. Several smaller, privately family owned competitors exist, including Double Eagle Leathersmith, Montana Leather Company, and Weaver Leather Supply.
The table above illustrates a few of Tandy's unique values and attributes. Such as EV/OI = 8.8, P/NCAV = 1.13, and 85.50M cumulative EBIT over the prior 15 years and 121.28M for EBITDA. This is versus an enterprise value of 39M.
Opportunity:
Tandy Leather reported fourth-quarter and year-end 2023 results on 03/22/24. For the year ending 2023, Tandy shows continued profit growth and cash in a difficult retail environment with high inflation. Net income was $3.80 million, an increase of $1.20 million compared to the year ending 2022. Gross profit was relatively flat as margins improved from 57.90% in 2022 to 59.30% in 2023. Operating expenses declined 9.70% to a stable operating expense of 40 million. Cash grew to 12.20 million from 8 million in 2022. After adjusting for stock compensation, EBITDA was 6.50 million.
TLF is an intrinsically and relatively cheap investment based on consistent profitable FCF and growing margins. Deep value-based and long term owners provide a margin of safety and offer constructive activism. Bandera (Jeff Gramm) owns 34.40%, JCP Investment(James Pappas) 10.04%, and First Foundation (Eric Speron )10%. CEO Janet Carr owns 4.50%.
Karnalyte Resources (KRN.TO / KRLTF) was founded in 2007 and listed on the Toronto Stock Exchange in December 2010. The $65-million IPO raised $14 million more than expected.
KRLTF : Price = .15, market cap = 9.86M, enterprise value = 7.47M as of 03/11/24
Based on the 2016 National Instrument 43-101 Technical Report filed at sedar.com their Wynyard Project is projected to mine 2.125 million tons of potash annually. Additionally, a nitrogen project exists. Approximately 700 metric tons of ammonia and 1,200 metric tons of urea per day can be produced. Nitrogen's target customer is independent fertilizer wholesalers in Central Saskatchewan. The 43-101 report covers geology, mining, recovery methods, required infrastructure, mineral resources, and mineral reserves estimations.
Further, Fortune India 500 Gujarat State Fertilizers & Chemicals (GSFC) is Karnalyte's largest shareholder. As of 2024, GFSC still supports Wynyard Potash and Proteus Nitrogen projects. Gujarat State Fertilizers & Chemicals has contractually guaranteed a long term availability to purchase Karnalyte's potash. Detailed engineering has been completed, and all environmental permits remain valid. Funding and market conditions determine Karnalyte's progress.
Karnalyte Resources' investment potential is impressive.
Karnalyte's largest shareholder is Indian agribusiness giant Gujarat State Fertilizers & Chemicals (GSFC). A placement happened in January 2013 for 8.15 Canadian Dollars per share. Karnalyte's current enterprise value is 5.74M, and its market cap is 7.51 M. This compares favorably to the 19.80% ownership or a 40 million GFSC 2013 investment.
Potential valuation:
In June 2016, Karnalyte received the National Instrument 43-101 Technical Report for its Wynyard Potash Project. The report verified a staggering amount of mineral assets.
Potash Project (Bankable Feasibility Study in Canadian dollars)
“NPV (8% ) $3.39 Billion for all 3 phases (after tax), IRR 19.1% for 3 Phases, 2.125 million tpy project (after tax), CAPEX for Phase 1 $789 Million ($2.396 Billion for all 3 phases) Cost per installed tonne of Capacity $1,262 for Phase 1 ($1127 for all 3 phases)Proven & Probable Reserves of 147 million tonnes KCl, Estimated Mine Life over 70 years for 3 Phases, 2.125 million tpy project”
Magnesium Project (Preliminary Feasibility Study)
"Considers annual production of 100,000 tonnes of MgCl2 brine and 104,000 tonnes of 99+% Hydromagnesite (BMC). Construction assumed after phase 1 of potash)"
"NPV (10%) $512 Million (after tax), IRR 26.1% (after tax),CAPEX (additional to Phase 1) $171 million,OPEX for MgCl2 Brine $7.01 per tonne,OPEX for Hydromagnesite $302.01 per tonne,Probable Reserves for MgCl2 694.6 million tonnes of carnallitite @ 22.1% MgCl2, equivalent to 153.3 million tonnes “mineable” and 7.9 million tonnes of product"
Karnalyte's mineral assets have staggering potential. There is a possibility of billions in potash and magnesium before operation costs. "There's enough potash there to sustain the world for I don't know how many years," said Dave Van Dam, a prominent Kenora businessman and Karnalyte shareholder. "It's monstrous."